April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Narsoplimab Exceeds Expectations Across High-Risk HSCT-TMA Subtype
May 14th 2021Administered narsoplimab in patients with high-risk hematopoietic stem cell transplant– associated thrombotic microangiopathy resulted in a response rate of 61% among all patients treated with the monoclonal antibody
Read More
Clinical Pearls in Management of Relapsed/Refractory Follicular Lymphoma
April 22nd 2021Citing clinical pearls from her own experience in working with patients with relapsed/refractory follicular lymphoma, Kami Maddocks, MD, gives advice to colleagues in their efforts to combat follicular lymphoma.
Watch
Treatment Challenges Beyond Second-Line in Relapsed/Refractory Follicular Lymphoma
April 22nd 2021The challenges faced in treating patients beyond second-line treatment are addressed. Kami Maddocks, MD, reviews the frequency of patients who require third- and fourth-line treatment, in addition to the factors that affect treatment decisions in later lines of therapy.
Watch
Phase 3 Study of Imtelstat Versus BAT Explores Survival Improvement in Myelofibrosis
April 15th 2021A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.
Read More
Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma
April 15th 2021Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/
Read More